ArticleScientific reports2014
mtDNA germ line variation mediated ROS generates retrograde signaling and induces pro-cancerous metabolic features.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Article
- Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer.Journal of translational medicine · 2024Review
- Loss of Cardiac Splicing RegulatorJACC. Basic to translational science · 2024Article
- Article
- Intimate Relations-Mitochondria and Ageing.International journal of molecular sciences · 2020Review
- Mitochondrial Genome (mtDNA) Mutations that Generate Reactive Oxygen Species.Antioxidants (Basel, Switzerland) · 2019Review
- Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity.Cells · 2019Review
- Insights into the respiratory chain and oxidative stress.Bioscience reports · 2018Review
- Mitochondrial genome analysis in penile carcinoma.Molecular biology reports · 2018Article
- DNA Methyltransferase1 (DNMT1) Isoform3 methylates mitochondrial genome and modulates its biology.Scientific reports · 2017Article
- Human Mitochondrial Cytochrome b Variants Studied in Yeast: Not All Are Silent Polymorphisms.Human mutation · 2016Article
- Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism.Cellular and molecular life sciences : CMLS · 2016Review
- Mitochondrial genome instability in colorectal adenoma and adenocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
mtDNA non-synonymous germ line variation (G10398A; p.A114T) has remained equivocal with least mechanistic understanding in showing an association with cancer. This has necessitated showing in-vitro how an over-expression within mitochondria of either of the variants produces higher intracellular ROS, resulting in differential anchorage dependent and independent growth. Both these features were observed to be relatively higher in ND3:114T variant. An elevated amount of intracellular carbonylated proteins and a reduced activity of a key glycolytic enzyme, Pyruvate kinase M2, along with high glucose uptake and lactate production were other pro-cancerous features observed. The retrograde signaling through surplus ROS was generated by post-ND3 over-expression regulated nuclear gene expression epigenetically, involving selectively the apoptotic-DDR-pathways. The feature of ND3 over-expression, inducing ROS mediated pro-cancerous features in the cells in in vitro, was replicated in a pilot study in a limited number of sporadic breast tumors, suggesting the importance of mitochondrial germ-line variant(s) in enabling the cells to acquire pro-cancerous features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.